Our client was a large, commercial-stage biotech company with a broad portfolio of marketed and development-stage products that treat life-threatening diseases in several therapeutic areas. Leaders at the company recognized several resource, capability, and strategic gaps in the way they plan for and execute commercialization of therapies with companion diagnostics (CDx) and sought a partner in Promidian to address this problem.
Promidian first collected and analyzed a fact base of information relating to companion diagnostics, based on currently available internal and external CDx intelligence. The Promidian team then conducted a series of internal interviews to validate in-going insights and assumptions about our client’s current CDx needs, capabilities, and planning processes.
Following the internal interviews, we facilitated a strategic workshop with more than 30 key internal CDx stakeholders to define strengths, gaps, and initial recommendations by comparing the fact base to the internal assumptions we collected. We also used the workshop to define a five-year CDx strategy for the organization.
Next, we proposed and supported execution of six distinct work streams—aligned to the strategy—that focused on establishing organization-wide CDx capabilities, tools, and processes. Lastly, we developed a CDx strategy and planning roadshow presentation that was endorsed by senior leadership prior to broad socialization.